Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Benedetto Maurizio Celesia"'
Autor:
Stefano Renzetti, Matteo Siano, Stefania Piconi, Agostino Riva, Jovana Milic, Anna Maria Cattelan, Giuseppe Vittorio De Socio, Stefano Calza, Matteo Rota, Emanuele Focà, Giancarlo Orofino, Giovanni Di Perri, Anna Celotti, Giovanni Guaraldi, Benedetto Maurizio Celesia, Andrea Calcagno, Silvia Nozza
Publikováno v:
AIDS. 35:939-945
Objective The aim of this study was to explore weight gain in people with HIV (PWH) at least 65 years of age who switch to a DTG based regimen (DTG-s) vs. remaining INSTI-naive (INSTI-n) on stable ART. Methods This was a longitudinal prospective stud
Autor:
Alessandra Vergori, Elio Manzillo, Roberta Termini, Andrea Antinori, Diego Ripamonti, Antonella dʼArminio Monforte, Christof Stingone, Nicola Gianotti, Stefano Savinelli, Benedetto Maurizio Celesia, Francesco Castelli, Renato Maserati, Teresa Santantonio, Giancarlo Orofino, Barbara Menzaghi, Francesco Rucci, Maria Vittoria Cossu, Roberto Cauda, Gaetana Sterrantino, Anna Maria Cattelan, Alessia Uglietti, Andrea Gori, Stefano Rusconi, Daniela Mancusi, Stefano Bonora
Publikováno v:
Journal of Acquired Immune Deficiency Syndromes (1999)
Objective: This study investigates the effectiveness and tolerability of switching to a darunavir/cobicistat (DRV/c)-based antiretroviral regimen from a ritonavir-boosted protease inhibitor (PI/r)-based regimen in virologically suppressed HIV-positiv
Autor:
Stefano Renzetti, Jovana Milic, Giuseppe Vittorio De Socio, Emanuele Focà, Francesco Castelli, Micol Ferrara, Giovanni Guaraldi, Annacarla Chiesa, Silvia Nozza, Anna Maria Cattelan, Stefania Piconi, Andrea Calcagno, Giordano Madeddu, Benedetto Maurizio Celesia, Matteo Siano, Giancarlo Orofino, Stefano Calza
Publikováno v:
PLoS ONE
PLoS ONE, Vol 16, Iss 10, p e0258533 (2021)
PLoS ONE, Vol 16, Iss 10, p e0258533 (2021)
Objective To investigate the durability of the first integrase inhibitor-based regimen in a HIV geriatric multicentric prospective cohort and to explore the reasons of regimen discontinuation. Design This is an analysis conducted on the Geriatric Pat
Autor:
Emanuele Focà, Silvia Nozza, Antonio Muscatello, Stefano Rusconi, Gabriella d'Ettorre, Alessandra Bandera, Ilaria De Benedetto, Andrea Giacomelli, Andrea Antinori, Benedetto Maurizio Celesia, Massimiliano Fabbiani, Giordano Madeddu, Cristina Mussini, Giulia Marchetti
Publikováno v:
Journal of Medical Virology. 91:1891-1895
To assess the impact of genotypic susceptibility score (GSS) on combined antiretroviral therapy (cART) outcomes during primary HIV infection (PHI) we retrospectively enrolled patients with PHI diagnosed between 2008 and 2015 at 9/24 Italian Network A
Autor:
Nicola Squillace, Lucia Taramasso, Benedetto Maurizio Celesia, Elena Ricci, Giancarlo Orofino, Giuseppe Vittorio De Socio, Paolo Bonfanti, Giordano Madeddu, Roberto Gulminetti, Giovanni Francesco Pellicanò, Barbara Menzaghi, Chiara Dentone, Paola Bagella
Publikováno v:
Infection and Drug Resistance
Paola Bagella,1 Nicola Squillace,2 Elena Ricci,3 Roberto Gulminetti,4 Giuseppe Vittorio De Socio,5 Lucia Taramasso,6 Giovanni Pellicanò,7 Barbara Menzaghi,8 Benedetto Maurizio Celesia,9 Chiara Dentone,10 Giancarlo Orofino,11 Paolo Bonfanti,12 Giorda
Autor:
Brenda Homony, Claudine Duvivier, I Neves, Christine Katlama, Gordon Crofoot, Natalia Zakharova, Stefan Esser, Hedy Teppler, Xia Xu, Randi Y. Leavitt, Adriano Lazzarin, CR Mejia, M Mustafa, Olga Aleksandrovna Tsybakova, James H McMahon, Brian Conway, Juan Carlos Rondon, Faiza Ajana, TS Chow, M Oyanguren, EM Rojas, Jean-Michel Molina, A Avihingsanon, Carlos Perez, Koldo Aguirrebengoa, Karen T. Tashima, M Wolff, Yazdan Yazdanpanah, Eugenia Negredo, R Serrao, Richard James Moore, Carmen D. Zorrilla, Winai Ratanasuwan, C Echiverri, L Panther, Joel E. Gallant, Andri Rauch, HH Lin, Bernard Vandercam, Anthony John Scarsella, L Hercilla, A. Antinori, Pedro Cahn, Albrecht Stoehr, DE Sweet, Mariette E. Botes, Johannes R. Bogner, Hans Jaeger, Soumi Gupta, Olaf Degen, Nathan Clumeck, H. Hartl, PJ Ruane, Ckc Lee, Juergen K. Rockstroh, Richard Kaplan, N Roth, MF Lasso, Rassool, Gatell Jm, Markus Bickel, Nelson, M Moutschen, V Sotnikov, R Kaplan, Amanda Clarke, WH Sheng, Anchalee Avihingsanon, Doug Ward, L Vanderkerckhove, Daniel S Berger, Sasisopin Kiertiburanakul, Ghr Smith, Sandy L. Rawlins, Mohammed Rassool, A d'Arminio Monforte, Paul E. Sax, Margaret A. Johnson, F. Maggiolo, Fernando Maltez, Ramirez, Evgeny Voronin, Eyal Shahar, S Henn, Cheryl McDonald, A Ustianowski, MT Bloch, E Arathoon, Peter Sklar, LD Gonzalez, Enrique Ortega, Louis Sloan, Amneris E. Luque, Isabelle Poizot-Martin, M. H. Losso, Giuliano Rizzardini, Debbie Hagins, Lilly East, Andrea Gori, Matthias Cavassini, Princy Kumar, Isabel Cassetti, G. Di Perri, Benedetto Maurizio Celesia, Evelyn Rojas, S Ferret, Jerry L. Cade, KM Mullane, CB Hsiao, Dane Turner, Eugénio Teófilo, Bach-Yen Nguyen, Craig A. Dietz, Anthony Rodgers, Elena Orlova-Morozova, Z. Sthoeger, Jean-Guy Baril, Hila Elinav, I Khaertynova, JG Saraiva da Cunha, Carl J. Fichtenbaum, G Faetkanheuer, Peter Ruane, HC Tsai, R Iskandar Shah Raja Azwa, Lerato Mohapi, Firaya Nagimova, Keikawus Arastéh, J. Durant, JD Velez, Jacques Reynes, ST Lewis, Saag, Otto Sussmann, P. Cahn, D Changpradub, Mark Bloch, RM Novak, W Ratanasuwan, Kathleen Squires, Fiona Smaill, Larissa Wenning, Jose R. Arribas, Edwin DeJesus, Don Smith, JO Morales, A. Yakovlev, Sharon Walmsley, Carolina Eugenia Chahin, I Levy, Alexandra Calmy, David James Prelutsky, David M. Asmuth, Linos Vandekerckhove, J Troya, Antonio Antela, Alan Winston, Lizette Santiago, Juan Berenguer, Marcel Stoeckle, RA Castillo, Anita Rachlis
Publikováno v:
Lancet HIV
Lancet HIV, Elsevier, 2017, 4 (11), pp.e486-e494. ⟨10.1016/S2352-3018(17)30128-5⟩
LANCET HIV
The Lancet HIV, Vol. 4, No 11 (2017) pp. e486-e494
Lancet HIV, Elsevier, 2017, 4 (11), pp.e486-e494. ⟨10.1016/S2352-3018(17)30128-5⟩
LANCET HIV
The Lancet HIV, Vol. 4, No 11 (2017) pp. e486-e494
Summary Background Once daily regimens are preferred for HIV-1 treatment, to facilitate adherence and improve quality of life. We compared a new once daily formulation of raltegravir to the currently marketed twice daily formulation. Methods In this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b080de940b6244d90b7b170ca487b8b0
https://hal.archives-ouvertes.fr/hal-01745628
https://hal.archives-ouvertes.fr/hal-01745628
Autor:
Tiziana Quirino, Laura Carenzi, Paola Corsi, Marta Guastavigna, Giustino Parruti, Giovanni Penco, Giuseppe Vittorio De Socio, Antonio Di Biagio, Paolo Bonfanti, Chiara Molteni, Canio Martinelli, Marco Franzetti, Elena Ricci, Barbara Menzaghi, C Grosso, Giancarlo Orofino, Giordano Madeddu, Benedetto Maurizio Celesia, Francesca Vichi, Paolo Maggi
Publikováno v:
Biomedicine & Pharmacotherapy. 67:293-298
Objective: To evaluate safety and durability of once-daily and twice-daily darunavir/ritonavir (DRV/r)-based treatment in HIV patients in clinical practice. Methods: The Surveillance Cohort Long-Term Toxicity Antiretrovirals (SCOLTA) project is a pro
Publikováno v:
Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish. 4:grhta.5000266
Budget impact analysis in the maintenance raltegravir-containing regimen in virologically suppressed HIV infected patientsBackgroundA one-year cost analysis was conducted to estimate the impact fro...
Autor:
Benedetto Maurizio Celesia, Simona Landonio, Antonio Di Biagio, Barbara Menzaghi, Marianna Meschiari, Sara Melzi, Paola Meraviglia, Amedeo Capetti, Giovanni Francesco Pellicanò, Alessandro Soria, Giuliano Rizzardini, Sergio Lo Caputo, Elena Mazzotta, Laura Carenzi, Giuseppe Vittorio De Socio, Michele Trezzi, Lolita Sasset, Gaetana Sterrantino, Adriana Ammassari, Marco Franzetti, Elena Ricci
Apart from the BENCHMRK study, there are no large observational experiences describing the long-term efficacy and safety of rescue regimens for human immunodeficiency virus type 1 (HIV-1) infection. Antiretroviral-experienced patients with detectable
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a86106ed21b16a28222aef0d2db27aba
https://hdl.handle.net/11380/1258995
https://hdl.handle.net/11380/1258995
Autor:
N Storaci, L. Guarneri, R. La Rosa, P. Bellissima, A Zagami, G. Mannino, D Ingrassia, S. Cosentino, Tullio Prestileo, F. Di Lorenzo, G. Scifo, V. Portelli, M. Gussio, Claudia Colomba, S. Galvagna, Alfredo Franco, Benedetto Maurizio Celesia, A. Salvo, A. Davì, L. Nigro, Giuseppe Nunnari, S. Migliore, Filippo Palermo, G Sturniolo, S. Bruno, G Todaro
Purpose of the study : Maraviroc (MVC) is the first CCR5 inhibitor licensed for clinical use. A pre-treatment test is mandatory to identify R5 tropic patients. Aim of this study is to detect indications and results of tropism test and to evaluate eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed48833f99a61949aff76878c5d13815
https://hdl.handle.net/20.500.11769/552165
https://hdl.handle.net/20.500.11769/552165